Diagnosis of prostate cancer using carbon-11 labeled choline PET/CT

Diagnosis of prostate cancer using carbon-11 labeled choline PET/CT - Choline PET/CT for prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013377

Enrollment

Registered

2014-03-13

Start date

2014-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

PET/CT imaging will be performed 5 min after injection of 11C-Choline. Images will be evaluated for the detection of lymphnode/bone metastasis.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients of high risk group of prostate cancer: PSA level over 20ng/mL, Gleason score over 8. Patients suspected of recurrence of prostate cancer after therapy: Re-elevation of PSA level.

Exclusion criteria

Exclusion criteria: Those who have not signed the informed consent form. Those who are severe systemic condition with serious underlying disease. Those who have been decided not appropriate for enrollment by the investigator.

Design outcomes

Primary

Measure	Time frame
Positive predictive value	—

Secondary

Measure	Time frame
Additional information with 11C-choline PET/CT. Sensitivity. Clinical impact.	—

Countries

Japan

Contacts

Public ContactKazuo Kubota, Yoko Miyata, Momoko Okasaki

National Center for Global Health and Medicine Div.Nuclear Medicine, Dept.Radiology

rikensa@lily.ocn.ne.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026